Buy Like Buffett
Watchlist

Flagship explainer

How BridgeBio Pharma, Inc. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$502M · 100%Cost of revenue$21M · 4%Gross profit$481M · 96%Operating income−$523M · −104%Income before tax−$733M · −146%Income tax$435000 · 0%Net income−$733M · −146%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$502M100%
  • 10-K · FY 2025Filing detailsAccession 0001743881-26-000009 · filed Feb 24, 2026
Cost of revenue$21M4%
  • 10-K · FY 2025Filing detailsAccession 0001743881-26-000009 · filed Feb 24, 2026
$481M96%
  • 10-K · FY 2025Filing detailsAccession 0001743881-26-000009 · filed Feb 24, 2026
−$523M−104%
  • 10-K · FY 2025Filing detailsAccession 0001743881-26-000009 · filed Feb 24, 2026
Income before tax−$733M−146%
  • 10-K · FY 2025Filing detailsAccession 0001743881-26-000009 · filed Feb 24, 2026
Income tax$4350000%
  • 10-K · FY 2025Filing detailsAccession 0001743881-26-000009 · filed Feb 24, 2026
−$733M−146%
  • 10-K · FY 2025Filing detailsAccession 0001743881-26-000009 · filed Feb 24, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001743881-26-000009 · filed Feb 24, 2026
· event Dec 31, 2025 · retrieved Oct 18, 2026 · annual-row source set
Embed this chart

View the full BridgeBio Pharma, Inc. analysis at Buy Like Buffett